Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CODX NASDAQ:FEMY NASDAQ:OSRH NASDAQ:POAI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCODXCo-Diagnostics$1.29-21.2%$1.91$1.26▼$46.50$5.87M1.26735,483 shs413,980 shsFEMYFemasys$0.36-6.3%$0.45$0.31▼$1.11$22.99M-2.26422,241 shs242,103 shsOSRHOSR$0.57-5.0%$0.54$0.38▼$1.79$21.07M0.8617.86 million shs1.16 million shsPOAIPredictive Oncology$5.85+4.5%$3.80$0.71▼$16.54$19.86M1.35473,545 shs345,832 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCODXCo-Diagnostics-21.17%-49.21%-9.51%-48.39%-87.57%FEMYFemasys-6.31%-17.05%-16.88%-29.83%-66.04%OSRHOSR-5.00%-0.09%+4.28%+14.92%-51.28%POAIPredictive Oncology-13.58%-1.23%+61.38%+129.51%-65.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCODXCo-Diagnostics$1.29-21.2%$1.91$1.26▼$46.50$5.87M1.26735,483 shs413,980 shsFEMYFemasys$0.36-6.3%$0.45$0.31▼$1.11$22.99M-2.26422,241 shs242,103 shsOSRHOSR$0.57-5.0%$0.54$0.38▼$1.79$21.07M0.8617.86 million shs1.16 million shsPOAIPredictive Oncology$5.85+4.5%$3.80$0.71▼$16.54$19.86M1.35473,545 shs345,832 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCODXCo-Diagnostics-21.17%-49.21%-9.51%-48.39%-87.57%FEMYFemasys-6.31%-17.05%-16.88%-29.83%-66.04%OSRHOSR-5.00%-0.09%+4.28%+14.92%-51.28%POAIPredictive Oncology-13.58%-1.23%+61.38%+129.51%-65.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCODXCo-Diagnostics 2.00Hold$67.505,152.92% UpsideFEMYFemasys 2.50Moderate Buy$5.331,395.61% UpsideOSRHOSR 1.00SellN/AN/APOAIPredictive Oncology 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CODX, FEMY, POAI, and OSRH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)3/27/2026OSRHOSR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/3/2026FEMYFemasys Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$1.50(Data available from 5/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCODXCo-Diagnostics$620K7.46N/AN/A$9.14 per share0.14FEMYFemasys$2.38M9.06N/AN/A$0.12 per share2.97OSRHOSR$2.91M6.89N/AN/A$3.63 per share0.16POAIPredictive Oncology$1.66M11.93N/AN/A($0.46) per share-12.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCODXCo-Diagnostics-$46.90M-$29.73N/AN/AN/A-6,760.63%-143.23%-125.49%N/AFEMYFemasys-$18.63M-$0.27N/AN/AN/A-521.97%-258.08%-73.72%N/AOSRHOSR-$27.06M-$0.33N/AN/AN/A-363.26%-7.24%-5.41%N/APOAIPredictive Oncology-$12.66M-$13.50N/AN/AN/A-5,065.23%-732.73%-235.55%N/ALatest CODX, FEMY, POAI, and OSRH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CODXCo-Diagnostics-$3.75-$4.06-$0.31-$4.06$0.13 million$0.15 million5/13/2026Q1 2026OSRHOSRN/A-$0.09N/A-$0.09N/A$0.48 million5/8/2026Q1 2026FEMYFemasys-$0.0667$0.0049+$0.0716N/A$0.77 million$0.42 million3/31/2026Q4 2025CODXCo-Diagnostics-$3.90-$16.65-$12.75-$16.65$0.13 million$0.26 million3/31/2026Q4 2025FEMYFemasys-$0.0833-$0.01+$0.0733-$0.01$1.06 million$0.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCODXCo-DiagnosticsN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/APOAIPredictive OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCODXCo-DiagnosticsN/A3.873.59FEMYFemasys0.533.912.95OSRHOSRN/A0.160.15POAIPredictive OncologyN/A0.010.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCODXCo-Diagnostics14.99%FEMYFemasys65.27%OSRHOSR55.30%POAIPredictive Oncology9.04%Insider OwnershipCompanyInsider OwnershipCODXCo-Diagnostics5.40%FEMYFemasys7.55%OSRHOSR60.60%POAIPredictive Oncology1.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCODXCo-Diagnostics1003.60 million3.41 millionOptionableFEMYFemasys3060.39 million55.83 millionNot OptionableOSRHOSRN/A35.11 million13.83 millionN/APOAIPredictive Oncology303.39 million3.35 millionNot OptionableCODX, FEMY, POAI, and OSRH HeadlinesRecent News About These CompaniesPredictive Oncology (NASDAQ:POAI) Share Price Crosses Above 200-Day Moving Average - Should You Sell?May 16 at 4:22 AM | americanbankingnews.comHead-To-Head Survey: Predictive Oncology (NASDAQ:POAI) versus Zepp Health (NYSE:ZEPP)May 5, 2026 | americanbankingnews.comPredictive Oncology announces name change to Axe ComputeDecember 12, 2025 | msn.comPredictive Oncology rebrands to Axe Compute Inc.December 11, 2025 | msn.comPredictive Oncology Regains Nasdaq ComplianceDecember 2, 2025 | tipranks.comPredictive Oncology regains compliance with Nasdaq minimum stockholder equityDecember 2, 2025 | msn.comPredictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementDecember 2, 2025 | markets.businessinsider.comPredictive Oncology Regains Nasdaq Compliance with InvestmentsNovember 20, 2025 | tipranks.comPredictive Oncology Expands into Digital Asset ManagementNovember 20, 2025 | msn.comPredictive Oncology Inc. (POAI) Q3 2025 Earnings Call Prepared Remarks TranscriptNovember 17, 2025 | seekingalpha.comPredictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset StrategyNovember 14, 2025 | globenewswire.comAI in Predictive Toxicology Market Outlook 2025–2032: Strong CAGR of 29.7% with USD 3,925.5 Million ValuationNovember 11, 2025 | finance.yahoo.comPredictive Oncology Updates ATM Offering ProgramOctober 29, 2025 | tipranks.comPredictive Oncology files to sell 5.97M shares of common stock for holdersOctober 22, 2025 | msn.comAethir's $344M GPU DAT Looks To Move Crypto Treasuries From Michael Saylor's Strategy Model to Something More SustainableOctober 21, 2025 | finance.yahoo.comPredictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury StrategyOctober 14, 2025 | globenewswire.comPredictive Oncology Secures $343.5 Million Investment to Launch World’s First Strategic Compute Reserve and Enhance AI-Driven Drug Discovery EffortsOctober 8, 2025 | quiverquant.comQPredictive Oncology Inc. Announces Closing of $343.5 Million in Private Placements to Initiate Digital Asset Treasury StrategyOctober 8, 2025 | globenewswire.comPredictive Oncology Announces $344.4M Private PlacementsSeptember 30, 2025 | msn.comPredictive Oncology Stock Receives Significant Investor Interest Today – Here Are Two Important DevelopmentsSeptember 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCODX, FEMY, POAI, and OSRH Company DescriptionsCo-Diagnostics NASDAQ:CODX$1.28 -0.35 (-21.17%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1.28 0.00 (0.00%) As of 05/15/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Femasys NASDAQ:FEMY$0.36 -0.02 (-6.31%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$0.37 +0.01 (+4.04%) As of 05/15/2026 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.OSR NASDAQ:OSRH$0.57 -0.03 (-5.02%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$0.57 +0.00 (+0.35%) As of 05/15/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.Predictive Oncology NASDAQ:POAI$5.85 +0.25 (+4.46%) As of 05/15/2026Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
